BCWorldPharm Co Ltd

BCWorldPharm's capital structure is characterized by a debt-to-equity ratio of 1.22, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.55, suggesting limited short-term liquidity to cover current liabilities. Free cash flow is positive at 800.63 million KRW, but operating cash flow of 5.58 billion KRW is insufficient to cover the long-term debt of 87.16 billion KRW. Profitability metrics show a return on equity of -6.87% and a return on assets of -2.77%, both significantly below the industry median for pharmaceutical companies, which typically report positive ROE and ROA. The company's net income is negative at -4.90 billion KRW, indicating a loss-making position despite a gross profit of 30.59 billion KRW. The company's revenue is concentrated in a single business segment focused on pharmaceuticals, with no disclosed geographic diversification. This lack of segment or geographic diversification increases exposure to market-specific risks. No specific revenue concentration by region is provided, but the company's operations are based in South Korea, which may limit its exposure to global markets. Outlook for the current fiscal year shows a negative revenue trajectory, with a net loss of 4.90 billion KRW. No specific growth projections are provided for the next fiscal year, but the company's capital expenditure of -4.01 billion KRW suggests a reduction in investment activity. The company's operating cash flow of 5.58 billion KRW provides some buffer against short-term obligations, but long-term debt remains a concern. Risk factors include a negative net cash position after subtracting total debt, which raises liquidity concerns. The company's dilution risk is assessed as low, with no near-term pressure from share issuance or convertible debt. No recent events such as filings or transcripts are disclosed in the provided data, limiting insight into management's strategic direction.